NOX Stock Overview
Noxopharm Limited, a biotech company, discovers and develops treatments for cancer and inflammation, and mRNA vaccines in Australia.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Noxopharm Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | AU$0.067 |
52 Week High | AU$0.17 |
52 Week Low | AU$0.033 |
Beta | 0.71 |
1 Month Change | 11.67% |
3 Month Change | -5.63% |
1 Year Change | -36.19% |
3 Year Change | -89.37% |
5 Year Change | -82.60% |
Change since IPO | -63.78% |
Recent News & Updates
Recent updates
Is Noxopharm (ASX:NOX) In A Good Position To Deliver On Growth Plans?
Jan 04We're Keeping An Eye On Noxopharm's (ASX:NOX) Cash Burn Rate
Jul 22Is Noxopharm (ASX:NOX) In A Good Position To Deliver On Growth Plans?
Feb 27We Think Noxopharm (ASX:NOX) Can Easily Afford To Drive Business Growth
Nov 10Is Noxopharm (ASX:NOX) Using Debt Sensibly?
Jun 04Noxopharm (ASX:NOX) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Feb 17These 4 Measures Indicate That Noxopharm (ASX:NOX) Is Using Debt Extensively
Sep 04Shareholder Returns
NOX | AU Biotechs | AU Market | |
---|---|---|---|
7D | -9.5% | 2.7% | 1.5% |
1Y | -36.2% | 1.4% | 11.6% |
Return vs Industry: NOX underperformed the Australian Biotechs industry which returned 1.4% over the past year.
Return vs Market: NOX underperformed the Australian Market which returned 11.6% over the past year.
Price Volatility
NOX volatility | |
---|---|
NOX Average Weekly Movement | 18.7% |
Biotechs Industry Average Movement | 11.5% |
Market Average Movement | 8.7% |
10% most volatile stocks in AU Market | 17.1% |
10% least volatile stocks in AU Market | 3.2% |
Stable Share Price: NOX's share price has been volatile over the past 3 months.
Volatility Over Time: NOX's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2015 | n/a | Gisela Mautner | https://www.noxopharm.com |
Noxopharm Limited, a biotech company, discovers and develops treatments for cancer and inflammation, and mRNA vaccines in Australia. It primarily develops Veyonda, a formulation of idronoxil for the treatment of solid tumors. The company also develops LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; and IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types.
Noxopharm Limited Fundamentals Summary
NOX fundamental statistics | |
---|---|
Market cap | AU$19.58m |
Earnings (TTM) | -AU$12.13m |
Revenue (TTM) | AU$3.88m |
5.1x
P/S Ratio-1.6x
P/E RatioIs NOX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
NOX income statement (TTM) | |
---|---|
Revenue | AU$3.88m |
Cost of Revenue | AU$6.30m |
Gross Profit | -AU$2.43m |
Other Expenses | AU$9.70m |
Earnings | -AU$12.13m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.041 |
Gross Margin | -62.60% |
Net Profit Margin | -312.86% |
Debt/Equity Ratio | 0% |
How did NOX perform over the long term?
See historical performance and comparison